Stryker Corporation $SYK Shares Sold by Villere ST Denis J & Co. LLC

Villere ST Denis J & Co. LLC lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 3.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 77,859 shares of the medical technology company’s stock after selling 3,192 shares during the period. Stryker comprises 2.7% of Villere ST Denis J & Co. LLC’s portfolio, making the stock its 12th largest holding. Villere ST Denis J & Co. LLC’s holdings in Stryker were worth $27,365,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. KLP Kapitalforvaltning AS grew its position in shares of Stryker by 0.3% in the 4th quarter. KLP Kapitalforvaltning AS now owns 123,284 shares of the medical technology company’s stock worth $43,423,000 after acquiring an additional 360 shares in the last quarter. Accretive Wealth Partners LLC raised its position in shares of Stryker by 10.8% during the 4th quarter. Accretive Wealth Partners LLC now owns 2,716 shares of the medical technology company’s stock valued at $955,000 after acquiring an additional 264 shares in the last quarter. L. Roy Papp & Associates LLP raised its position in shares of Stryker by 1.1% during the 4th quarter. L. Roy Papp & Associates LLP now owns 64,681 shares of the medical technology company’s stock valued at $22,733,000 after acquiring an additional 683 shares in the last quarter. CPC Advisors LLC acquired a new stake in shares of Stryker during the 4th quarter valued at approximately $890,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of Stryker by 4.5% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 448,358 shares of the medical technology company’s stock valued at $158,012,000 after acquiring an additional 19,138 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.7%

Shares of NYSE SYK opened at $329.63 on Thursday. The company has a market cap of $126.24 billion, a price-to-earnings ratio of 39.24, a price-to-earnings-growth ratio of 1.91 and a beta of 0.92. Stryker Corporation has a 12-month low of $319.32 and a 12-month high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The stock’s 50 day simple moving average is $351.26 and its 200 day simple moving average is $358.80.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The business had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the business posted $4.01 EPS. Equities research analysts expect that Stryker Corporation will post 14.92 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 41.90%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Needham & Company LLC upped their price target on Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Jefferies Financial Group reissued a “buy” rating and set a $465.00 price target on shares of Stryker in a research report on Wednesday, March 4th. Leerink Partners assumed coverage on Stryker in a research report on Monday, April 13th. They set an “outperform” rating and a $410.00 price target on the stock. Piper Sandler reissued an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. Finally, Robert W. Baird set a $437.00 price target on Stryker in a research report on Friday, January 30th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $421.11.

Insider Activity

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.